Literature DB >> 24417657

Mimicking red blood cell lipid membrane to enhance the hemocompatibility of large-pore mesoporous silica.

Robert A Roggers1, Madhura Joglekar, Justin S Valenstein, Brian G Trewyn.   

Abstract

Mesoporous silica nanoparticles (MSNs) have been repeatedly demonstrated as potential drug-delivery devices. The study of biocompatibility and interaction of these materials with the various cell types is of great interest with regard to the development of viable pharmaceutical products. By mimicking the cholesterol, phosphatidylcholine, and phosphatidylethanolamine composition of the outer leaflet of a human red blood cell (RBC), lipid-bilayer-coated mesoporous silica particles show considerably improved hemocompatibility over phosphatidylcholine-coated and uncoated large-pore MSN (l-MSN). These inorganic/organic composite nanomaterials are shown to be capable of interfacing with RBCs without damaging the cells even at relatively high concentrations, as observed through electron microscopy, UV-vis spectroscopy, and flow cytometry analyses. Interestingly, the absence of cholesterol in the outer bilayer composition is shown to produce toxic effects without resulting in hemolysis. By maintaining the ζ potential of lipid-bilayer-functionalized MSNs similar to that of the hemolytic l-MSNs, we demonstrate that the bilayer composition, and not the surface charge, plays a significant role in determining the hemocompatibility of MSN-based materials.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24417657     DOI: 10.1021/am4045713

Source DB:  PubMed          Journal:  ACS Appl Mater Interfaces        ISSN: 1944-8244            Impact factor:   9.229


  6 in total

Review 1.  Protocells: Modular Mesoporous Silica Nanoparticle-Supported Lipid Bilayers for Drug Delivery.

Authors:  Kimberly S Butler; Paul N Durfee; Christophe Theron; Carlee E Ashley; Eric C Carnes; C Jeffrey Brinker
Journal:  Small       Date:  2016-01-18       Impact factor: 13.281

2.  Regulating intracellular fate of siRNA by endoplasmic reticulum membrane-decorated hybrid nanoplexes.

Authors:  Chong Qiu; Hu-Hu Han; Jing Sun; Hai-Tao Zhang; Wei Wei; Shi-He Cui; Xin Chen; Jian-Cheng Wang; Qiang Zhang
Journal:  Nat Commun       Date:  2019-06-20       Impact factor: 14.919

Review 3.  Controlled drug delivery systems for cancer based on mesoporous silica nanoparticles.

Authors:  Nerea Iturrioz-Rodríguez; Miguel A Correa-Duarte; Mónica L Fanarraga
Journal:  Int J Nanomedicine       Date:  2019-05-08

Review 4.  Applications and Biocompatibility of Mesoporous Silica Nanocarriers in the Field of Medicine.

Authors:  Chengcheng Zhang; Hongyi Xie; Zhengyan Zhang; Bingjian Wen; Hua Cao; Yan Bai; Qishi Che; Jiao Guo; Zhengquan Su
Journal:  Front Pharmacol       Date:  2022-01-28       Impact factor: 5.810

5.  SBA-15 Mesoporous Silica as Delivery Vehicle for rhBMP-2 Bone Morphogenic Protein for Dental Applications.

Authors:  Dimitrios Gkiliopoulos; Ioannis Tsamesidis; Anna Theocharidou; Georgia K Pouroutzidou; Evi Christodoulou; Evangelia Stalika; Konstantinos Xanthopoulos; Dimitrios Bikiaris; Konstantinos Triantafyllidis; Eleana Kontonasaki
Journal:  Nanomaterials (Basel)       Date:  2022-02-28       Impact factor: 5.076

Review 6.  Synthesis and compatibility evaluation of versatile mesoporous silica nanoparticles with red blood cells: an overview.

Authors:  Subhankar Mukhopadhyay; Hanitrarimalala Veroniaina; Tadious Chimombe; Lidong Han; Wu Zhenghong; Qi Xiaole
Journal:  RSC Adv       Date:  2019-11-01       Impact factor: 4.036

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.